18F-ASIS PET/CT Imaging of Tissue Factor Expression In Patients With Primary and Metastastic Cancer
Status:
Completed
Trial end date:
2019-11-18
Target enrollment:
Participant gender:
Summary
The primary objective of the trial is to test the new radio tracer 18F-ASIS for PET imaging
of tissue factor (TF) expression. The tracer has the potential of identifying tumors with
high levels of TF expression, which is expected to correlate with tumor aggression and
prognosis. Furthermore, the tracer can potentially be used as companion imaging diagnostic
agent for identifying patients eligible for TF directed therapies.
This is a first-in-man study to test the radio tracer in cancer patients. Safety,
biodistribution and dosimetry will be evaluated by repeated PET imaging (1 hour, 2 hours and
4 hours post-injection).